Replimune, Inc.
REPL · Nasdaq · United States
Share price · REPL
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when REPL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 2 Nov 2026+10.7%
Nothing announced by REPL that day or the session before.
- 28 Oct 2026+23.1%
- 31 Jul 2026+107.0%
- 28 Jul 2026-38.0%
Nothing announced by REPL that day or the session before.
- 29 May 2026+85.7%
- 13 May 2026+29.6%
Nothing announced by REPL that day or the session before.
- 23 Apr 2026+25.6%
Nothing announced by REPL that day or the session before.
- 13 Apr 2026-64.3%
- 10 Apr 2026-19.5%
Nothing announced by REPL that day or the session before.
- 8 Apr 2026-24.6%
Nothing announced by REPL that day or the session before.
Share of unusual movement by asset
For each asset, the share of REPL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Vusolimogene oderparepvec (Tudriqev) (Tudriqev)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 62% |
| Sessions with no dated event | — | 37% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | No discrete molecular targetOncolytic virus | Non-Small Cell Lung CancerMelanoma | |
| Phase 2/3 | Oncolytic HSV-1 (tumour lysis and immune stimulation)Oncolytic virus | Uveal Melanoma |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
What to watch
2028 (1)
June 2028 (1)
What to watch
2029 (1)
July 2029 (1)
What to watch
2030 (1)
January 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $34M | $310M+ $0 short-term inv. | $57M-$48M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $49M | $187M+ $10.0M short-term inv. | $70M-$76M operating cash flow | report ↗ |
| 2025-Q4 | — | $53M | $125M+ $146M short-term inv. | $71M-$66M operating cash flow | report ↗ |
| 2025-Q3 | — | $58M | $104M+ $221M short-term inv. | $83M-$81M operating cash flow | report ↗ |
| 2025-Q2 | — | $58M | $99M+ $306M short-term inv. | $87M-$77M operating cash flow | report ↗ |
| 2024-Q4 | — | $48M | $174M+ $364M short-term inv. | $66M-$51M operating cash flow | report ↗ |
| 2024-Q3 | — | $43M | $115M+ $319M short-term inv. | $53M-$39M operating cash flow | report ↗ |
| 2024-Q2 | — | $43M | $153M+ $317M short-term inv. | $54M-$49M operating cash flow | report ↗ |
| 2023-Q4 | — | $43M | $99M+ $369M short-term inv. | $51M-$47M operating cash flow | report ↗ |
| 2023-Q3 | — | $49M | $78M+ $421M short-term inv. | $60M-$44M operating cash flow | report ↗ |
| 2023-Q2 | — | $40M | $108M+ $433M short-term inv. | $50M-$49M operating cash flow | report ↗ |
| 2022-Q4 | — | $30M | $208M+ $410M short-term inv. | $40M-$29M operating cash flow | report ↗ |
| 2022-Q3 | — | $29M | $91M+ $283M short-term inv. | $43M-$33M operating cash flow | report ↗ |
| 2022-Q2 | — | $29M | $114M+ $283M short-term inv. | $42M-$33M operating cash flow | report ↗ |
| 2021-Q4 | — | $19M | $134M+ $288M short-term inv. | $30M-$18M operating cash flow | report ↗ |
| 2021-Q3 | — | $20M | $162M+ $276M short-term inv. | $29M-$23M operating cash flow | report ↗ |
Annual history (6 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | — | $221M | $211M+ $60M short-term inv. | $78M-$280M operating cash flow | report ↗ |
Replimune did not disclose revenue for fiscal year 2026, and prior-year revenue was also not disclosed. R&D expense was $221.18M, up 16.7% YoY from $189.45M. Cash and equivalents were $210.73M, while cash, cash equivalents and short-term investments totaled $268.9M as of March 31, 2026. The company reported a net loss of $313.94M for the fiscal year.
The FDA accepted for review the resubmitted BLA for RP1 in combination with nivolumab for advanced melanoma, with a goal date of August 2, 2026 and an advisory committee meeting expected in late July. The company highlighted durable survival data from the IGNYTE trial, active enrollment in the IGNYTE-3 and REVEAL trials, and a planned Phase 2/3 transition in Q1 2027. Based on its current operating plan, existing cash, cash equivalents and short-term investments are expected to fund operations into the first quarter of calendar 2027, excluding any potential revenue.
View 5 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $189M | $113M+ $373M short-term inv. | $62M-$192M operating cash flow | report ↗ |
| 2024-FY | — | $175M | $76M+ $346M short-term inv. | $54M-$185M operating cash flow | report ↗ |
| 2023-FY | — | $127M | $148M+ $437M short-term inv. | $44M-$128M operating cash flow | report ↗ |
| 2022-FY | — | $80M | $108M+ $290M short-term inv. | $30M-$82M operating cash flow | report ↗ |
| 2021-FY | — | $57M | $184M+ $294M short-term inv. | $20M-$61M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 21 sales ($4.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Hill Emily Luisa · Chief Financial Officer | Open-market sale | 14,709 | $21.60 | $318K | Form 4 |
| 2026-11-16 | Patel Sushil · director, Chief Executive Officer | Open-market sale | 49,026 | $21.60 | $1.1M | Form 4 |
| 2026-11-16 | Schwendenman Andrew · Chief Accounting Officer | Open-market sale | 2,148 | $21.60 | $46K | Form 4 |
| 2026-11-16 | Xynos Konstantinos · Chief Medical Officer | Open-market sale | 16,198 | $21.60 | $350K | Form 4 |
| 2026-11-09 | SLATTERY JOSEPH P · director | Open-market sale | 5,200 | $21.80 | $113K | Form 4 |
| 2026-11-02 | Dhingra Kapil · director | Option exercise | 43,169 | $1.75 | $76K | Form 4 |
| 2026-11-02 | Dhingra Kapil · director | Open-market sale | 21,500 | $19.00 | $409K | Form 4 |
| 2026-11-02 | Dhingra Kapil · director | Option exercise (derivative) | 43,169 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 179 reporting institutions held 81.1M shares ($552.6M, 86.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 11,045,336 | $84.5M |
| 2 | RTW INVESTMENTS, LP | 7,356,916 | $56.3M |
| 3 | BlackRock, Inc. | 6,239,239 | $47.7M |
| 4 | SUVRETTA CAPITAL MANAGEMENT, LLC | 4,221,836 | $32.3M |
| 5 | STATE STREET CORP | 3,782,237 | $28.9M |
| 6 | FCPM III SERVICES B.V. | 2,808,368 | $21.5M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 2,759,120 | $21.1M |
| 8 | D. E. Shaw & Co., Inc. | 2,336,528 | $17.9M |
| 9 | GOLDMAN SACHS GROUP INC | 2,277,276 | $17.4M |
| 10 | FMR LLC | 2,045,490 | $15.6M |
| 11 | Erste Asset Management GmbH | 2,120,000 | $15.3M |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 1,801,525 | $13.8M |
| 13 | TORONTO DOMINION BANK | 1,591,030 | $12.2M |
| 14 | ADAR1 Capital Management, LLC | 1,582,987 | $12.1M |
| 15 | Boxer Capital Management, LLC | 1,175,000 | $9.0M |